STOCK TITAN

HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

HUTCHMED (HCM) announced expanded Chinese national drug reimbursement coverage for ELUNATE and ORPATHYS, effective January 1, 2027, following contract renewal.

ELUNATE gains coverage with sintilimab for locally advanced or metastatic kidney cancer after prior VEGFR-targeted therapy failed, excluding patients who received first-line PD-1 or PD-L1 inhibitors. ORPATHYS gains coverage with osimertinib for locally advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer with MET amplification after progression on EGFR-targeted therapy. Coverage is also renewed for ORPATHYS in adults with locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping alteration. All other previously included indications for ELUNATE, ORPATHYS and SULANDA remain covered under current multi-year agreements.

Loading...
Loading translation...
4 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.ELUNATE reimbursement expands with sintilimab for locally advanced or metastatic renal cell carcinoma after failed VEGFR tyrosine kinase inhibitor therapy, without prior first-line PD-1 or PD-L1 inhibitor therapy.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.ORPATHYS reimbursement expands with osimertinib for locally advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer with MET amplification after progression on EGFR tyrosine kinase inhibitors.
  • Minor pointORPATHYS coverage renewed for adults with locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping alteration.
  • Minor pointOther previously included indications remain covered for ELUNATE, ORPATHYS and SULANDA under current multi-year agreements.

Negative

  • None.

Key Figures

Updated NRDL effective date: January 1, 2027
Updated NRDL effective date
January 1, 2027
Updated National Reimbursement Drug List

Historical Context

1 past event · Latest: Nov 01
1 event
  1. Nov 01

    ORPATHYS regulatory filings

    24h Move
    +0.9%

    European and Japanese review accepted for ORPATHYS plus TAGRISSO in post-EGFR-targeted lung cancer.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

vegfr, tki, pd-1, pd-l1, +2 more
6 terms
vegfr medical
"vascular endothelial growth factor receptor (“VEGFR”)"
VEGFR is a protein on the surface of cells that acts like a doorbell for signals that tell the body to grow new blood vessels. Investors care because therapies or tests that block or measure VEGFR can slow blood-vessel growth in tumors or abnormal eye conditions, affecting the potential value of drugs, diagnostics, and related companies; think of it as a light switch that controls a supply line to tissues, and changing it can change a company’s market prospects.
tki medical
"tyrosine kinase inhibitors (“TKI”) therapy"
A TKI (tyrosine kinase inhibitor) is a type of drug that blocks specific enzymes cells use to send growth signals, effectively slowing or stopping the proliferation of certain cancer and disease cells. For investors, TKIs matter because they are often central to a biotech company's product pipeline and revenue potential: successful TKIs can win regulatory approval, command premium pricing, and shift competitive dynamics in treatment markets, much like a key component that can make or break a new technology's commercial success.
pd-1 medical
"programmed death receptor-1 (PD-1)"
PD-1 is a protein found on certain immune cells that acts like a brake, signaling the immune system to slow down and avoid damaging healthy tissue. Drugs that block PD-1 release that brake so immune cells can better attack cancer cells; because such therapies can produce large clinical benefits, regulatory approvals, trial outcomes, pricing and market uptake for PD-1 drugs can materially affect a drugmaker’s prospects and investor returns.
pd-l1 medical
"programmed death-ligand 1 (PD-L1)"
PD-L1 is a protein found on the surface of some cells that acts like a stop sign for the immune system, telling certain immune cells to back off. It matters to investors because many cancer drugs and diagnostic tests target or measure PD-L1 to unlock immune responses or predict which patients will benefit, affecting clinical success, regulatory approval, and potential sales in the oncology market.
nsclc medical
"non-small cell lung cancer (“NSCLC”)"
NSCLC stands for non-small cell lung cancer, which is the most common type of lung cancer. It develops in the lungs and can spread to other parts of the body, making it serious but often treatable if caught early. Understanding NSCLC helps people recognize the importance of lung health and early detection.
met amplification medical
"EGFR mutation-positive non-squamous non-small cell lung cancer (“NSCLC”) with MET amplification"
MET amplification is a genetic change where extra copies of the MET gene cause cells to make too much of a growth-promoting protein, which can drive some cancers to grow and spread. For investors, it matters because cancers with this change may respond to targeted drugs or diagnostic tests, affecting the commercial potential of therapies, clinical trial outcomes, and the value of companies developing treatments or tests for MET-driven tumors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 15, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that following the contract renewal with the China National Healthcare Security Administration (“NHSA”), the updated National Reimbursement Drug List (“NRDL”) effective on January 1, 2027 will continue to include ELUNATE®, ORPATHYS® and SULANDA®. This update reflects expanded coverage for new indications, renewed agreements for existing indications, as well as continued inclusion under current multi-year agreements.

Newly Included and Renewed Indications in the Updated NRDL:

  • ELUNATE® (fruquintinib) is newly included for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior vascular endothelial growth factor receptor (“VEGFR”) tyrosine kinase inhibitors (“TKI”) therapy and have not received programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor therapy in the first-line setting, in combination with sintilimab injection.

  • ORPATHYS® (savolitinib) is newly included for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation-positive non-squamous non-small cell lung cancer (“NSCLC”) with MET amplification after disease progression on EGFR-TKI therapy, in combination with osimertinib. It is also renewed for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration. 

In addition to the above updates, the NRDL maintains coverage for all other previously included indications for ELUNATE®, ORPATHYS® and SULANDA® under their current multi-year agreement.

The government in China has placed great importance on improving the affordability of drug treatments for the public. As of end of 2025, 1.33 billion people in China had basic medical insurance coverage, representing around 95% of the entire population. The NRDL is updated every year, and inclusion on the list is subject to renewal every two years. The NHSA annually convenes a broad network of experts in medicine, pharmacology, pharmacoeconomics and actuarial valuation to identify innovative medicines to consider for NRDL inclusion. Reimbursement of Category B medicines, including novel oncology medicines, requires varying degrees of copayment from patients, depending on their provinces or types of NHSA insurance scheme enrollment.

About Fruquintinib

Fruquintinib is a selective oral inhibitor of all three VEGFR -1, -2 and -3. Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE®. Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA®.

About Savolitinib

Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. Savolitinib is being jointly developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca under the brand name ORPATHYS®.

About Surufatinib

Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells. Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA®. HUTCHMED currently retains all rights to surufatinib worldwide.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations for the commercialization of fruquintinib, savolitinib and surufatinib in China, the potential benefits and further clinical development of fruquintinib, savolitinib and surufatinib, its expectations as to whether further studies would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the commercial acceptance of fruquintinib, savolitinib and surufatinib, the impact of the inclusion of fruquintinib, savolitinib and surufatinib on the NRDL on sales of the drug and its pricing, clinical trial enrollment rates, timing and availability of subjects meeting a study’s inclusion and exclusion criteria, changes to clinical protocols or regulatory requirements, unexpected adverse events or safety issues, the ability of fruquintinib, savolitinib and surufatinib to obtain regulatory approval for a targeted indication in different jurisdictions and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products such as sintilimab or osimertinib as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries+852 2121 8200 /ir@hutch-med.com
  
Media Enquiries 
FTI Consulting –+44 20 3727 1030 /HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi+852 9783 6894 (Mobile) /HUTCHMED@brunswickgroup.com
  
Panmure LiberumNominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden+44 20 7886 2500
  
CavendishJoint Broker
Geoff Nash / Nigel Birks+44 20 7220 0500
  
Deutsche NumisJoint Broker
Duncan Monteith / Ramin Naji+44 20 7545 8000
  



FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does HUTCHMED's expanded ELUNATE and ORPATHYS reimbursement coverage take effect?

The updated National Reimbursement Drug List takes effect on January 1, 2027. It adds indications for ELUNATE and ORPATHYS while maintaining coverage for all other previously included indications for those medicines and SULANDA.

Does Chinese national reimbursement eliminate patient copayments for HUTCHMED's cancer medicines?

Category B medicines, including novel oncology medicines, require patient copayments. The amount varies depending on the patient's province or type of National Healthcare Security Administration insurance scheme enrollment.

Keep reading